|
US4447233A
(en)
|
1981-04-10 |
1984-05-08 |
Parker-Hannifin Corporation |
Medication infusion pump
|
|
US4439196A
(en)
|
1982-03-18 |
1984-03-27 |
Merck & Co., Inc. |
Osmotic drug delivery system
|
|
US4447224A
(en)
|
1982-09-20 |
1984-05-08 |
Infusaid Corporation |
Variable flow implantable infusion apparatus
|
|
US4487603A
(en)
|
1982-11-26 |
1984-12-11 |
Cordis Corporation |
Implantable microinfusion pump system
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US4596556A
(en)
|
1985-03-25 |
1986-06-24 |
Bioject, Inc. |
Hypodermic injection apparatus
|
|
ATE87659T1
(de)
|
1986-09-02 |
1993-04-15 |
Enzon Lab Inc |
Bindungsmolekuele mit einzelpolypeptidkette.
|
|
US5260203A
(en)
|
1986-09-02 |
1993-11-09 |
Enzon, Inc. |
Single polypeptide chain binding molecules
|
|
US4941880A
(en)
|
1987-06-19 |
1990-07-17 |
Bioject, Inc. |
Pre-filled ampule and non-invasive hypodermic injection device assembly
|
|
US4790824A
(en)
|
1987-06-19 |
1988-12-13 |
Bioject, Inc. |
Non-invasive hypodermic injection device
|
|
US4949778A
(en)
|
1987-12-16 |
1990-08-21 |
Kawasaki Steel Corporation |
Immersion nozzle for continuous casting
|
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
|
US5312335A
(en)
|
1989-11-09 |
1994-05-17 |
Bioject Inc. |
Needleless hypodermic injection device
|
|
US5064413A
(en)
|
1989-11-09 |
1991-11-12 |
Bioject, Inc. |
Needleless hypodermic injection device
|
|
EP0786469B1
(en)
|
1990-06-11 |
2006-03-01 |
Gilead Sciences, Inc. |
Methods of use of nucleic acid ligands
|
|
DE69232137T2
(de)
|
1991-11-25 |
2002-05-29 |
Enzon Inc |
Multivalente antigen-bindende proteine
|
|
US5383851A
(en)
|
1992-07-24 |
1995-01-24 |
Bioject Inc. |
Needleless hypodermic injection device
|
|
US6005079A
(en)
|
1992-08-21 |
1999-12-21 |
Vrije Universiteit Brussels |
Immunoglobulins devoid of light chains
|
|
AU701578B2
(en)
|
1992-08-21 |
1999-02-04 |
Vrije Universiteit Brussel |
Immunoglobulins devoid of light chains
|
|
WO1994025591A1
(en)
|
1993-04-29 |
1994-11-10 |
Unilever N.V. |
PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE)
|
|
SE9400088D0
(sv)
|
1994-01-14 |
1994-01-14 |
Kabi Pharmacia Ab |
Bacterial receptor structures
|
|
WO1996002561A1
(en)
|
1994-07-20 |
1996-02-01 |
The General Hospital Corporation |
Interaction trap systems for detecting protein interactions
|
|
DE19742706B4
(de)
|
1997-09-26 |
2013-07-25 |
Pieris Proteolab Ag |
Lipocalinmuteine
|
|
AUPP221098A0
(en)
|
1998-03-06 |
1998-04-02 |
Diatech Pty Ltd |
V-like domain binding molecules
|
|
GB9818110D0
(en)
|
1998-08-19 |
1998-10-14 |
Weston Medical Ltd |
Needleless injectors and other devices
|
|
US6096002A
(en)
|
1998-11-18 |
2000-08-01 |
Bioject, Inc. |
NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method
|
|
US6818418B1
(en)
|
1998-12-10 |
2004-11-16 |
Compound Therapeutics, Inc. |
Protein scaffolds for antibody mimics and other binding proteins
|
|
EP1696038B1
(en)
|
1999-05-05 |
2010-06-02 |
Phylogica Limited |
Isolating biological modulators from biodiverse gene fragment libraries
|
|
AU4761100A
(en)
|
1999-05-26 |
2000-12-18 |
Kalle Saksela |
Methods and materials for generating sh3 domains with tailored binding properties
|
|
SE0001877D0
(sv)
|
2000-05-22 |
2000-05-22 |
Klaus Mosbach |
Molecular imprinting
|
|
DE60140474D1
(de)
|
2000-09-08 |
2009-12-24 |
Univ Zuerich |
Sammlung von proteinen mit sich wiederholenden sequenzen (repeat proteins), die repetitive sequenzmodule enthalten
|
|
US7998681B2
(en)
|
2000-10-06 |
2011-08-16 |
Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center |
Diagnosis and therapy of antibody-mediated inflammatory auto-immune disorders
|
|
US8153121B2
(en)
|
2000-10-06 |
2012-04-10 |
Los Angeles Biomedical Research Institute at Harbor—UCLA Medical Center |
Diagnosis and therapy of antibody-mediated inflammatory autoimmune disorders
|
|
DE10053224A1
(de)
|
2000-10-26 |
2002-05-08 |
Univ Goettingen Georg August |
Verfahren zur Exposition von Peptiden und Polypeptiden auf der Zelloberfläche von Bakterien
|
|
PT1355919E
(pt)
|
2000-12-12 |
2011-03-02 |
Medimmune Llc |
Moléculas com semivida longa, composições que as contêm e suas utilizações
|
|
US20040132094A1
(en)
|
2000-12-13 |
2004-07-08 |
Michael Etzerodt |
Combinatorial libraries of proteins having the scaffold structure of c-type lectinlike domains
|
|
BRPI0116728B1
(pt)
|
2001-01-05 |
2018-10-30 |
Pfizer Inc. |
anticorpos para receptor de fator de crescimento i semelhante à insulina
|
|
RU2004109222A
(ru)
|
2001-08-30 |
2005-10-20 |
Байорексис Фармасьютикал Корпорейшн (Us) |
Слитые белки модифицированного трансферрина
|
|
US7241444B2
(en)
|
2002-01-18 |
2007-07-10 |
Pierre Fabre Medicament |
Anti-IGF-IR antibodies and uses thereof
|
|
US20030206898A1
(en)
|
2002-04-26 |
2003-11-06 |
Steven Fischkoff |
Use of anti-TNFalpha antibodies and another drug
|
|
US7217796B2
(en)
|
2002-05-24 |
2007-05-15 |
Schering Corporation |
Neutralizing human anti-IGFR antibody
|
|
US8034904B2
(en)
|
2002-06-14 |
2011-10-11 |
Immunogen Inc. |
Anti-IGF-I receptor antibody
|
|
US7538195B2
(en)
|
2002-06-14 |
2009-05-26 |
Immunogen Inc. |
Anti-IGF-I receptor antibody
|
|
CA2501295A1
(en)
|
2002-10-02 |
2004-04-15 |
Jack Nguyen |
Methods of generating and screening for proteases with altered specificity
|
|
DK1587907T3
(da)
|
2003-01-07 |
2011-04-04 |
Dyax Corp |
Kunitz-domænebibliotek
|
|
AU2004212344B2
(en)
|
2003-02-13 |
2009-05-07 |
Pfizer Products Inc. |
Uses of anti-insulin-like growth factor I receptor antibodies
|
|
JP2007501021A
(ja)
|
2003-05-30 |
2007-01-25 |
アレクシオン ファーマシューティカルズ， インコーポレイテッド |
遺伝子操作された定常領域を含む、抗体および融合タンパク質
|
|
AR046071A1
(es)
|
2003-07-10 |
2005-11-23 |
Hoffmann La Roche |
Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos
|
|
PE20050928A1
(es)
|
2003-11-21 |
2005-11-08 |
Schering Corp |
Combinaciones terapeuticas de anticuerpo anti-igfr1
|
|
US20060008844A1
(en)
|
2004-06-17 |
2006-01-12 |
Avidia Research Institute |
c-Met kinase binding proteins
|
|
KR20070036130A
(ko)
|
2004-07-16 |
2007-04-02 |
화이자 프로덕츠 인코포레이티드 |
항-아이지에프-1알 항체를 사용하는 비-혈액학적악성종양에 대한 조합 치료
|
|
DE102004049479A1
(de)
|
2004-10-11 |
2006-04-13 |
Scil Proteins Gmbh |
Proteinkonjugate zur Verwendung in Therapie, Diagnose und Chromatographie
|
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
EP2283831A3
(en)
*
|
2004-12-03 |
2013-10-23 |
Merck Sharp & Dohme Corp. |
Biomakers for pre-selection of patients for anti-IGF1R therapy
|
|
MY146381A
(en)
|
2004-12-22 |
2012-08-15 |
Amgen Inc |
Compositions and methods relating relating to anti-igf-1 receptor antibodies
|
|
KR20080019249A
(ko)
|
2005-06-15 |
2008-03-03 |
쉐링 코포레이션 |
안정한 항체 제형
|
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
|
BRPI0617688A2
(pt)
|
2005-10-21 |
2011-06-07 |
Hoffmann La Roche |
método para expressão recombinante de um polipeptìdeo
|
|
WO2007062037A2
(en)
|
2005-11-21 |
2007-05-31 |
Laboratoires Serono Sa |
Compositions and methods of producing hybrid antigen binding molecules and uses thereof
|
|
US20080014203A1
(en)
|
2006-04-11 |
2008-01-17 |
Silke Hansen |
Antibodies against insulin-like growth factor I receptor and uses thereof
|
|
US20080112888A1
(en)
|
2006-06-30 |
2008-05-15 |
Schering Corporation |
Igfbp2 biomarker
|
|
US8603465B1
(en)
|
2006-08-07 |
2013-12-10 |
Merck Sharp & Dohme, Corp. |
Methods for treatment of polyposis
|
|
EP1892248A1
(en)
|
2006-08-21 |
2008-02-27 |
Eidgenössische Technische Hochschule Zürich |
Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase
|
|
EP2121018A2
(en)
|
2006-12-13 |
2009-11-25 |
Schering Corporation |
Treating cancer with anti-igf1r antibody 19d12=sch 717454
|
|
CA2672828A1
(en)
|
2006-12-13 |
2008-06-26 |
Schering Corporation |
Methods of treatment
|
|
US20090068110A1
(en)
|
2006-12-22 |
2009-03-12 |
Genentech, Inc. |
Antibodies to insulin-like growth factor receptor
|
|
US20080226635A1
(en)
|
2006-12-22 |
2008-09-18 |
Hans Koll |
Antibodies against insulin-like growth factor I receptor and uses thereof
|
|
CN101835802B
(zh)
|
2007-06-01 |
2014-04-09 |
马里兰大学巴尔的摩分校 |
免疫球蛋白恒定区Fc受体结合剂
|
|
US20110014117A1
(en)
|
2007-06-28 |
2011-01-20 |
Schering Corporation |
Anti-igf1r
|
|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
|
RU2529951C2
(ru)
|
2007-12-26 |
2014-10-10 |
Ксенкор, Инк. |
ВАРИАНТЫ Fc С ИЗМЕНЕННЫМ СВЯЗЫВАНИЕМ C FcRn
|
|
US20100260668A1
(en)
|
2008-04-29 |
2010-10-14 |
Abbott Laboratories |
Dual Variable Domain Immunoglobulins and Uses Thereof
|
|
WO2010005740A2
(en)
|
2008-06-16 |
2010-01-14 |
Bind Biosciences, Inc. |
Methods for the preparation of targeting agent functionalized diblock copolymers for use in fabrication of therapeutic targeted nanoparticles
|
|
NZ603698A
(en)
|
2008-07-08 |
2014-03-28 |
Abbvie Inc |
Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
|
|
BRPI0919034A8
(pt)
|
2008-09-26 |
2016-02-10 |
Schering Corp |
Métodos para produzir uma proteína e um anticorpo, meio líquido aquoso para cultura, e, vaso
|
|
US8137933B2
(en)
|
2008-11-12 |
2012-03-20 |
Schering Corporation |
Mammalian expression vector pUHAB
|
|
CN102481361B
(zh)
|
2009-04-16 |
2014-10-22 |
默沙东公司 |
用于治疗癌症的组合物和方法
|
|
NZ596711A
(en)
|
2009-05-01 |
2013-11-29 |
|
Dual variable domain immunoglobulins and uses thereof
|
|
KR101224468B1
(ko)
|
2009-05-20 |
2013-01-23 |
주식회사 파멥신 |
신규한 형태의 이중표적항체 및 그 용도
|
|
UY32808A
(es)
|
2009-07-29 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas como dominio variable dual y usos de las mismas
|
|
KR20120060877A
(ko)
|
2009-09-01 |
2012-06-12 |
아보트 러보러터리즈 |
이원 가변 도메인 면역글로불린 및 이의 용도
|
|
US9045536B2
(en)
|
2009-12-23 |
2015-06-02 |
Merck Sharp & Dohme Corp. |
Cell line 3M
|
|
WO2011161119A1
(en)
|
2010-06-22 |
2011-12-29 |
F. Hoffmann-La Roche Ag |
Antibodies against insulin-like growth factor i receptor and uses thereof
|
|
UY33492A
(es)
|
2010-07-09 |
2012-01-31 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
US20120100166A1
(en)
|
2010-07-15 |
2012-04-26 |
Zyngenia, Inc. |
Ang-2 Binding Complexes and Uses Thereof
|
|
JP5985481B2
(ja)
|
2010-09-01 |
2016-09-06 |
バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． |
抗イディオタイプ抗体の迅速な産生
|
|
US20120263722A1
(en)
|
2010-11-04 |
2012-10-18 |
Abbott Laboratories |
Dual Variable Domain Immunoglobulins and Uses Thereof
|
|
WO2012088302A2
(en)
|
2010-12-22 |
2012-06-28 |
Abbott Laboratories |
Half immunoglobulin binding proteins and uses thereof
|
|
WO2012116926A1
(en)
|
2011-02-28 |
2012-09-07 |
F. Hoffmann-La Roche Ag |
Antigen binding proteins
|
|
JP5768147B2
(ja)
|
2011-02-28 |
2015-08-26 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
一価抗原結合タンパク質
|
|
US9181304B2
(en)
|
2011-05-18 |
2015-11-10 |
University Of Florida Research Foundation, Inc. |
Macrocyclic therapeutic agents and methods of treatment
|
|
WO2012158657A1
(en)
|
2011-05-18 |
2012-11-22 |
Merck Sharp & Dohme Corp. |
Therapeutic anti-igf1r combinations
|
|
DK2714733T3
(da)
|
2011-05-21 |
2019-05-06 |
Macrogenics Inc |
Cd3-bindende molekyler, der er i stand til at binde til human og ikke-human cd3
|
|
BR112014016299A8
(pt)
|
2011-12-30 |
2017-07-04 |
Abbvie Inc |
imunoglobulinas de domínio variável e usos das mesmas
|
|
SG10201609500QA
(en)
|
2012-02-15 |
2016-12-29 |
Ecole Polytech |
Erythrocyte-binding therapeutics
|
|
EP2852685A1
(en)
|
2012-03-30 |
2015-04-01 |
Merck Sharp & Dohme Corp. |
Igf1 biomarker for igf1r inhibitor therapy
|
|
CN104994872B
(zh)
|
2012-06-21 |
2018-09-14 |
索伦托治疗有限公司 |
与igf1r结合的抗原结合蛋白
|
|
JP6586412B2
(ja)
|
2013-03-13 |
2019-10-02 |
バイオアシス テクノロジーズ インコーポレイテッド |
ｐ９７のフラグメントおよびその使用
|
|
KR20210094669A
(ko)
|
2013-04-29 |
2021-07-29 |
에프. 호프만-라 로슈 아게 |
인간 fcrn-결합 변형된 항체 및 사용 방법
|
|
EP3327034A1
(en)
|
2013-04-29 |
2018-05-30 |
F. Hoffmann-La Roche AG |
Fcrn-binding abolished anti-igf-1r antibodies and their use in the treatment of vascular eye diseases
|
|
RU2687043C2
(ru)
|
2013-04-29 |
2019-05-06 |
Ф. Хоффманн-Ля Рош Аг |
МОДИФИЦИРОВАННЫЕ АСИММЕТРИЧНЫЕ АНТИТЕЛА, СВЯЗЫВАЮЩИЕ Fc-РЕЦЕПТОР, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
|
|
BR112016015140A2
(pt)
|
2013-12-30 |
2018-01-23 |
Epimab Biotherapeutics Inc. |
imunoglobulina com fabs in-tandem e usos das mesmas
|
|
US20210138076A2
(en)
|
2014-01-27 |
2021-05-13 |
Molecular Templates, Inc. |
Cell-targeting molecules comprising shiga toxin a subunit effectors and cd8+ t-cell epitopes
|
|
WO2016004389A2
(en)
|
2014-07-03 |
2016-01-07 |
Abbvie Inc. |
Monovalent binding proteins
|
|
WO2016064716A1
(en)
|
2014-10-20 |
2016-04-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Combination therapy of tshr antagonist and igfr inhibitor
|
|
WO2017011773A2
(en)
|
2015-07-15 |
2017-01-19 |
Modernatx, Inc. |
Codon-optimized nucleic acids encoding antibodies
|
|
EP3448874A4
(en)
|
2016-04-29 |
2020-04-22 |
Voyager Therapeutics, Inc. |
COMPOSITIONS FOR TREATING A DISEASE
|
|
WO2017186928A1
(en)
|
2016-04-29 |
2017-11-02 |
Curevac Ag |
Rna encoding an antibody
|
|
EP3458101B1
(en)
|
2016-05-20 |
2020-12-30 |
H. Hoffnabb-La Roche Ag |
Protac antibody conjugates and methods of use
|
|
CN109803679A
(zh)
|
2016-08-30 |
2019-05-24 |
得克萨斯州大学系统董事会 |
在基因组重新编码生物体中生产硒代生物制剂
|
|
EP4596707A3
(en)
|
2016-09-19 |
2025-10-08 |
University of Southern California |
Non-radioactive cytotoxicity assays
|
|
US10722589B2
(en)
|
2017-04-03 |
2020-07-28 |
Covagen Ag |
FGFR3 binding molecules
|
|
US10093741B1
(en)
*
|
2017-05-05 |
2018-10-09 |
Fusion Pharmaceuticals Inc. |
IGF-1R monoclonal antibodies and uses thereof
|
|
CA3062538A1
(en)
|
2017-05-05 |
2018-11-08 |
Fusion Pharmaceuticals Inc. |
Igf-1r monoclonal antibodies and uses thereof
|
|
BR112019022789A2
(pt)
|
2017-05-30 |
2020-06-09 |
Teijin Pharma Ltd |
anticorpo do receptor de anti-igf-i ou fragmento do mesmo ou um derivado do mesmo, molécula de ácido nucleico, vetor de clonagem ou vetor de expressão, célula recombinante, processo de produção de um anticorpo do receptor de anti-igf-i ou fragmento do mesmo ou um derivado do mesmo, composição farmacêutica, medicamento, método para cultivar células derivadas de vertebrados in vitro, e, animal transgênico.
|
|
EP3700901A1
(en)
|
2017-10-24 |
2020-09-02 |
Genentech, Inc. |
(4-hydroxypyrrolidin-2-yl)-heterocyclic compounds and methods of use thereof
|
|
WO2019084030A1
(en)
|
2017-10-24 |
2019-05-02 |
Genentech, Inc. |
(4-HYDROXYPYRROLIDIN-2-YL) -HYDROXAMATE COMPOUNDS AND METHODS OF USE
|
|
US11208489B2
(en)
*
|
2018-01-24 |
2021-12-28 |
Horizon Therapeutics Ireland Dac |
Methods for the treatment of thyroid eye disease
|
|
US20210284741A1
(en)
|
2018-01-24 |
2021-09-16 |
Hznp Limited |
Methods for the treatment of thyroid eye disease
|
|
WO2019173352A1
(en)
*
|
2018-03-05 |
2019-09-12 |
Hznp Limited |
Methods for the treatment of thyroid eye disease
|
|
WO2019183523A1
(en)
|
2018-03-23 |
2019-09-26 |
Genentech, Inc. |
Hetero-bifunctional degrader compounds and their use as modulators of targeted ubiquination (vhl)
|
|
EP3866924A4
(en)
|
2018-06-29 |
2022-07-06 |
Krystal Biotech, Inc. |
COMPOSITIONS AND METHODS OF ANTIBODY DELIVERY
|
|
EA202191556A1
(ru)
|
2018-12-03 |
2021-10-14 |
Фьюжн Фармасьютикалз Инк. |
Комбинированная терапия радиоиммуноконъюгатами и ингибиторами контрольных точек
|
|
MX2021006756A
(es)
|
2018-12-19 |
2021-09-28 |
Humabs Biomed Sa |
Anticuerpos que neutralizan el virus de la hepatitis b y usos de los mismos.
|
|
BR112022003663A2
(pt)
*
|
2019-08-28 |
2022-05-24 |
Horizon Therapeutics Ireland Dac |
Método para tratar oftalmopatia tireoidiana (ted) em um indivíduo com ted; método para reduzir proptose em pelo menos 2 mm em um indivíduo com oftalmopatia tireoidiana (ted); método para tratar ou reduzir a gravidade de diplopia em um indivíduo com oftalmopatia tireoidiana (ted); método para tratar ou reduzir a gravidade de oftalmopatia tireoidiana (ted); método para reduzir proptose em um olho em um indivíduo com oftalmopatia tireoidiana (ted); método para reduzir pontuação de atividade clínica (cas) de oftalmopatia tireoidiana (ted); método para a) reduzir proptose em pelo menos 2 mm e b) reduzir a pontuação de atividade clínica (cas) em um indivíduo com oftalmopatia tireoidiana (ted); e método para melhorar a qualidade de vida em um indivíduo com oftalmopatia tireoidiana (ted)
|
|
CN113402602B
(zh)
|
2020-03-17 |
2022-09-23 |
上海祥耀生物科技有限责任公司 |
一种新型冠状病毒SARS-CoV-2中和性抗体及应用
|
|
WO2021243014A1
(en)
*
|
2020-05-28 |
2021-12-02 |
Horizon Therapeutics Ireland Dac |
Methods for the treatment of idiopathic orbital inflammation and related conditions
|
|
CN119792512A
(zh)
|
2020-10-14 |
2025-04-11 |
维里迪安治疗公司 |
用于治疗甲状腺眼病的组合物和方法
|
|
TW202246339A
(zh)
|
2021-03-03 |
2022-12-01 |
愛爾蘭商赫萊森治療愛爾蘭公司 |
治療甲狀腺眼疾的方法
|
|
EP4123454A1
(en)
|
2021-07-21 |
2023-01-25 |
Abb Schweiz Ag |
Validating component specifications for industrial automation systems
|
|
TW202320850A
(zh)
|
2021-08-10 |
2023-06-01 |
美商維里迪恩醫療股份有限公司 |
用於治療甲狀腺眼病之組合物、劑量及方法
|
|
MX2023015028A
(es)
|
2021-09-01 |
2024-02-16 |
Biosceptre Aust Pty Ltd |
Nuevos aglutinantes del p2x7 disfuncional.
|
|
WO2023122714A2
(en)
|
2021-12-23 |
2023-06-29 |
Viridian Therapeutics, Inc. |
Compositions and methods for treatment of thyroid eye disease
|
|
MX2024008529A
(es)
|
2022-01-07 |
2024-08-26 |
Viridian Therapeutics Inc |
Composiciones y metodos para el tratamiento de la enfermedad ocular tiroidea.
|
|
WO2023133485A2
(en)
|
2022-01-07 |
2023-07-13 |
Viridian Therapeutics, Inc. |
Compositions and methods for treatment of thyroid eye disease
|
|
JP2025503637A
(ja)
|
2022-01-09 |
2025-02-04 |
クリヤ セラピューティクス， インコーポレイテッド |
治療用抗ｉｇｆ－１ｒ抗体をコードする核酸の送達のためのベクター構築物およびそれを使用する方法
|
|
WO2025014774A1
(en)
|
2023-07-07 |
2025-01-16 |
Viridian Therapeutics, Inc. |
Methods of treating active and chronic thyroid eye disease
|
|
IL326876A
(en)
|
2023-09-06 |
2026-04-01 |
Viridian Therapeutics Inc |
Pharmaceutical preparations of anti-IGF-1R antibodies
|